Buprenorphine

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
3. 2026-09-07srcUse of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability
4. 2026-09-07srcVoriconazole greatly increases the exposure to oral buprenorphine
5. 2026-09-07srcTreating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
6. 2026-09-07srcA role for the mu opioid receptor in the antidepressant effects of buprenorphine
7. 2026-09-07srcHistory of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
8. 2026-09-07srcCharacterizing withdrawal from long-acting injectable buprenorphine: An observational case series
9. 2026-09-07srcComparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone
10. 2026-09-07srcHepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand
11. 2026-09-07srcBuprenorphine infrequently found in fatal overdose in New York City
12. 2026-09-07srcIntranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers
13. 2026-09-07srcEffects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials
14. 2026-09-07srcPharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder
15. 2026-09-07srcUrine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine
16. 2026-09-07srcBuprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active
17. 2026-09-07srcPregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine
18. 2026-09-07srcBuprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption
19. 2026-09-07srcThe Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal
20. 2026-09-07srcArrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration
21. 2026-09-07srcThe pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
22. 2026-09-07srcThe history and pharmacology of buprenorphine: New advances in cats
23. 2026-09-07srcDevelopment and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability
24. 2026-09-07srcMortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
25. 2026-09-07srcEvidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology
26. 2026-09-07srcThe use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies
27. 2026-09-07srcEvaluation of the Hepatotoxicity of Buprenorphine in Rat Pups Born to an Exposed Mother During Lactation
28. 2026-09-07srcPopulation pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
29. 2026-09-07srcBuprenorphine: The Opioid that Cried 'Partial Agonist'
30. 2026-09-07srcFlunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat
31. 2026-09-07srcBuprenorphine: new pharmacological aspects
32. 2026-09-07srcFlunitrazepam does not alter cerebral distribution of buprenorphine in the rat
33. 2026-09-07srcEffects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes
34. 2026-09-07srcDoes high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences
35. 2026-09-07srcBuprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures
36. 2026-09-07srcHuman pharmacokinetics of intravenous, sublingual, and buccal buprenorphine
37. 2026-09-07srcThe effects of buprenorphine in buprenorphine-maintained volunteers
38. 2026-09-07srcBuprenorphine Controlled Substance Scheduling: US Schedule III, UK Class C Schedule 3, Australia Schedule 8, Canada Narcotic Control Regulations
39. 2026-09-04issueIssued emergency
40. 2026-09-04issueIssued info_card
41. 2026-09-04issueIssued notice
42. 2026-07-03proposaldependence · taper
43. 2026-06-04proposal41 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
44. 2026-06-04publicationPublication — backfill
45. 2026-04-27revisionRevision 1
46. 2026-04-27absenceSearched PubMed for "buprenorphine intranasal insufflation bioavailability pharmacokinetics abuse" — no results
47. 2026-04-27genGeneration — pipeline-v5 · with 3 morepipeline-v5
48. 2026-04-27rungeneration run

The same entries, as forms: six forms.